Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) EBT (2016 - 2025)

Historic EBT for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to -$2.9 million.

  • Theravance Biopharma's EBT rose 7125.95% to -$2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.2 million, marking a year-over-year increase of 21609.45%. This contributed to the annual value of -$44.6 million for FY2024, which is 944.81% up from last year.
  • Per Theravance Biopharma's latest filing, its EBT stood at -$2.9 million for Q3 2025, which was up 7125.95% from $73.2 million recorded in Q2 2025.
  • Over the past 5 years, Theravance Biopharma's EBT peaked at $73.2 million during Q2 2025, and registered a low of -$79.5 million during Q1 2021.
  • Its 5-year average for EBT is -$19.8 million, with a median of -$14.3 million in 2022.
  • As far as peak fluctuations go, Theravance Biopharma's EBT plummeted by 7820.97% in 2024, and later surged by 58095.39% in 2025.
  • Theravance Biopharma's EBT (Quarter) stood at -$58.0 million in 2021, then surged by 75.4% to -$14.3 million in 2022, then skyrocketed by 64.82% to -$5.0 million in 2023, then tumbled by 78.21% to -$8.9 million in 2024, then surged by 67.68% to -$2.9 million in 2025.
  • Its EBT stands at -$2.9 million for Q3 2025, versus $73.2 million for Q2 2025 and -$14.1 million for Q1 2025.